
In a small study from France, an immune-dampening drug used by people battling rheumatoid arthritis showed promise in patients hospitalized with severe COVID-19. The drug, called anakinra, targets pro-inflammatory responses that kick into high gear in advanced COVID-19 — the so-called “cytokine storm.” A team led by Dr. Gilles Kaplanski, of the Public Assistance Hospital… read on >